Creating new cell therapies for lung diseases using AI technology
Development of Novel Regenerative Cell Therapies for Lung Diseases using AI-guided Chemical Reprogramming of Human Cells
This study is exploring a new way to help people with idiopathic pulmonary fibrosis (IPF) by using artificial intelligence to turn skin cells into lung cells, which could lead to better treatments for this serious lung disease.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellforma, INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10913890 on NIH RePORTER |
What this research studies
This research focuses on developing innovative cell therapies to treat idiopathic pulmonary fibrosis (IPF), a severe lung disease that leads to scarring and lung failure. The approach involves using artificial intelligence to identify effective chemical methods for reprogramming easily obtained skin cells into specialized lung cells. By leveraging AI and machine learning, the project aims to streamline the process of generating the necessary cells for therapy, potentially improving treatment options for patients with IPF. The research builds on previous findings that suggest cell replacement therapy could restore lung function in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with lung diseases other than idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have performed: While cell replacement therapy has shown promise in animal models, this specific approach using AI-guided chemical reprogramming is relatively novel and has not been extensively tested in humans.
Where this research is happening
Boston, United States
- Cellforma, INC — Boston, United States (Active)
Researchers
- Principal investigator: Ietswaart, Jaldert Hugo Rigobert — Cellforma, INC
- Study coordinator: Ietswaart, Jaldert Hugo Rigobert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.